Cormorant Private Healthcare Fund II, LP's Net Worth

$597 Million

Estimate Recalculated Feb 22, 2024 06:37PM EST

Who is Cormorant Private Healthcare Fund II, LP?

Cormorant Private Healthcare Fund II, LP has an estimated net worth of $597 Million. This is based on reported shares across multiple companies, which include Design Therapeutics, Inc., Atea Pharmaceuticals, Inc., Erasca, Inc., Monte Rosa Therapeutics, Inc., Aerovate Therapeutics, Inc., Avidity Biosciences, Inc., BioAtla, Inc., Rain Therapeutics Inc., Akouos, Inc., Olema Pharmaceuticals, Inc., GreenLight Biosciences Holdings, PBC, and MoonLake Immunotherapeutics.

SEC CIK

Cormorant Private Healthcare Fund II, LP's CIK is 0001747677

Past Insider Trading and Trends

2021 was Cormorant Private Healthcare Fund II, LP's most active year for acquiring shares with 15 total transactions. Cormorant Private Healthcare Fund II, LP's most active month to acquire stocks was the month of May. 2020 was Cormorant Private Healthcare Fund II, LP's most active year for disposing of shares, totalling 8 transactions. Cormorant Private Healthcare Fund II, LP's most active month to dispose stocks was the month of October. 2021 saw Cormorant Private Healthcare Fund II, LP paying a total of $56,250,000.00 for 35,787,698 shares, this is the most they've acquired in one year. In 2023 Cormorant Private Healthcare Fund II, LP cashed out on 9,188,659 shares for a total of $0.00, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Design Therapeutics, Inc. (DSGN) Snapshot price: $2.3

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
5.11M
$20.00
5.11M
Mar 30
Form 3
0
0
No matching records found

Atea Pharmaceuticals, Inc. (AVIR) Snapshot price: $4.15

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
6.41M
6.41M
Nov 3
Form 3
0
0
No matching records found

Erasca, Inc. (ERAS) Snapshot price: $1.7

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
Jun 22
Form 4/A
+2.93%
307.69K
$6.50
$1,999,998.00
10.81M
Dec 13
Form 4
+2.93%
307.69K
$6.50
$1,999,998.00
10.81M
Dec 13
Form 4
10.51M
$16.00
10.51M
Jul 20
Form 3/A
0
0
Form 3
0
0
No matching records found

Monte Rosa Therapeutics, Inc. (GLUE) Snapshot price: $4.68

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
3.2M
$19.00
3.2M
Jun 28
Form 3
0
0
No matching records found

Aerovate Therapeutics, Inc. (AVTE) Snapshot price: $20.52

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
2.03M
$14.00
2.03M
Jul 2
Form 3
0
0
No matching records found